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Dependence of Enhanced Maximal Exercise Performance on Increased
Peak Skeletal Muscle Perfusion During Long-Term Captopril Therapy
in Heart Failure
DONNA M, MANCINI, MD, LAWRENCE DAVIS, MD, JOHN P. WEXLER, MD, PHD,
BRIAN CHADWICK, RN, THIERRY H. LEJEMTEL, MD
Bronx, New York.
Maximal oxygen uptake (V02) , skeletal muscle blood
flow by xenon-133 washout technique and femoral vein
arteriovenous oxygen difference and lactate were mea-
sured at rest and during maximal bicycle exercise in eight
patients with severe congestive heart failure hefore and
after 8 weeks oftherapy with captopril. During therapy,
skeletal muscle blood flow at rest increased significantly
from 1.5 ± 0.6 to 2.6 ± 1.0 ml/l00 g per min (p <
0.05), with a concomitant decrease in the femoral ar-
teriovenous oxygen difference from 10.0 ± 1.7 to 8.3 ±
1.9 ml/l00 ml (p < 0.05). Maximal VOl increased sig-
nificantly from 13.4 ± 3.0 to 15.5 ± 4.1 ml/kg per min
(p < 0.05). In four patients, the increase in maximal
V02 averaged 3.7 ml/kg per min (range 2.7 to 4.9),
whereas in the remaining four patients, it was < I mJlkg
per min.
Overall, peak skeletal muscle blood flowattained dur-
ing exercise did not change significantly during long-
In patients with severe chronic congestive heart failure.
acute inhibition of angiotensin activation with captopril im-
proves cardiac performance at rest and during exercise. as
shown by an augmented cardiac output produced at lower
ventricular filling pressures. However. exercise capacity does
not improve immediately. as quantitated by maximal oxygen
uptake (V02 ) (1-5). Because systemic arteriovenous oxy-
gen difference decreases while femoral vein oxygen content
is unchanged, the increase in cardiac output is most likely
distributed to metabolically less active tissues. rather than
to the exercising skeletal muscles (4.5).
In contrast. during long-term therapy with captopril , a
majority of patients demonstrate some improvement in peak
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term therapy with captopril (19.6 ± 6.2 versus 27.6 ±
14.3 ml/IOO g per min, p = NS). However, the four
patients with a significant increase in maximal V02 ex-
perienced substantial increases in peak skeletal muscle
blood flow and the latter changes were linearly corre-
lated with changes in maximal VOl (r = 0.95, p <
0.00 I). Femoral arteriovenous oxygen difference at peak
exercise was unchanged (12.6 ± 2.6 versus 12.6 ± 2.4
ml/IOO ml).
Thus, improvement in maximal V02 produced by
long-term therapy with captopril is associated with an
increased peripheral vasodilatory response to exercise,
and this improvement only occurs when the peak blood
flow is augmented. Moreover, improvement in exercise
performance is not a result of heightened oxygen ex-
traction by the skeletal muscle.
(} Am Coil Cardiol 1987;10:845-50)
exercise capacity (6.7). The increase in maximal V02 could
result from either an increase in oxygen extraction by the
skeletal muscles. as observed during physical training, or
from an improvement in the capacity of the skeletal vas-
culature to vasodilate, resulting in an increase in skeletal
blood flow. Accordingly. the present study was undertaken
to investigate the relative contribution of these two mech-
anisms in patients with chronic congestive heart fai lure.
Skeletal muscle blood flow. evaluated by the xenon washout
technique, and oxygen extraction. assessed by determination
of femoral vein oxygen content. were measured at rest and
during maximal exercise before and after long-term admin-
istration of captopril.
Methods
Study patients. Eight men with chronic congestive heart
failure who were still symptomatic despite therapy with
furosemide (mean dose 112.5 mg daily. range 60 to 240)
0735-I097/~7/$3.50
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and digoxin (mean dose 0.24 mg daily, range 0.125 to
0.375) were studied. Their age averaged 57 years (range 38
to 77) and mean body weight was 68.4 kg (range 60 to
78.2). The cause of chronic heart failure was coronary artery
disease in five patients and idiopathic cardiomyopathy in
the remaining three. Exercise capacity was limited by gen-
eralized fatigue or dyspnea, or both, and not by angina. Six
patients were in functional class III, one was in functional
class IV and one was in functional class II according to the
New York Heart Association classification. Left ventricular
ejection fraction was ::;20% in all patients. The maximal
V02 averaged 13.4 ml/kg per min (range 9.5 to 20.0).
The risks of the study were fully explained to the patients,
and informed written consent was obtained. The protocol
was approved by the Committee on Clinical Investigations
of the Albert Einstein College of Medicine.
Study design. Maximal oxygen uptake (V02) , skeletal
muscle blood flow, femoral vein oxygen content and lactate
and radial artery oxygen content were measured at rest while
patients were sitting on an electronically braked bicycle
ergometer and during bicycling at a work load that yielded
a maximal V02 and resulted in exhaustion after 4 to 5
minutes. The maximal work load had been determined by
prior testing using a graded maximal stress test performed
on the same bicycle, starting at an initial work load of 15
W, with increments of 15 W every 4 minutes. Work loads
varied from 15 to 105 W, and averaged 30 W. All patients
had previously undergone several determinations of maxi-
mal V02 using a bicycle ergometer and, therefore, all were
familiar with the apparatus. The initial dose of captopril
was 6.25 mg administered every 8 hours. The dose was
titrated every 2 weeks to a daily dose of 75 mg for six
patients, and 37.5 mg for two patients who could not tolerate
higher doses as a result of symptomatic hypotension. The
daily dosage of furosemide was either decreased or un-
changed. The mean duration of therapy with captopril was
8 weeks (range 6 to 12). Exercise testing was repeated I
month after initiation of therapy and every 2 weeks there-
after.
Skeletalmusclebloodflow. This was determined at rest
and during exercise by the xenon clearance technique (8-12).
Xenon-133 (100 /LCi) was dissolved in 0.1 cc of normal
(0.9%) saline solution and injected into the lateral aspect
of the quadriceps muscle at a depth of 2.5 em, 15 cm above
the superior aspect of the patella and 2 em lateral to the
midline. The 25 gauge needle was withdrawn 30 seconds
after injection to avoid leakage of xenon-133 through the
puncture site. A I cm diameter cadmium telluride semi-
conductor detector (RMD) was affixed over the injection
depot with tape and adhesive. Activity was determined every
5 seconds for 10 minutes at rest and continued for at least
4 to 10 minutes during bicycle exercise. Data were acquired
directly into the memory of an IBM PC microcomputer,
which automatically stored, displayed and analyzed the count
data. Five second count rates versus time were plotted semi-
logarithmically. Skeletal muscle blood flow was derived
according to the equation: skeletal muscle blood flow = A
(slope) (100) (mIll 00 g per min). A value of 0.7 was used
for A, the partition coefficient of xenon between muscle
tissue and blood (13). The slope was calculated by the
computer from a least-square line fitted through the data
points.
The interfacing of the nonimaging cadmium telluride
semiconductor to a microcomputer for the acquisition, stor-
age and display of nuclear medicine data has been described
previously (14). Modification of this system warranted by
mechanical stress on the interface involved transfer of count-
ing and timing fractions from the counter scaler to the pe-
ripheral interface board (Metabyte Corporation, CTM-05,
Multifunction Counter Timer) in the microcomputer.
Reproducibility. Reproducibility of the xenon-133
washout technique to measure skeletal muscle blood flow
was assessed in seven untrained normal men, who exercised
on an upright bicycle at the same work load on 2 consecutive
days. Their average age was 31 years (range 29 to 43), and
their mean body weight was 73.8 kg (range 68.2 to 82).
Five subjects exercised at a work load of 100 W, and the
remaining two at 75 W. Rest and exercise skeletal muscle
blood flow were closely correlated during both tests (r =
0.97, P < 0.001). The V02 attained during exercise was
almost identical in both tests (22.0 ± 3.5 versus 22.4 ±
2.1 mllkg per min).
Oxygen uptake. Measurements of mixed expired oxy-
gen, mixed expired carbon dioxide, expired volume and
expired gas temperature were obtained at rest and every 30
seconds throughout exercise using a metabolic measurement
cart (Beckman Instruments). Maximal oxygen uptake (V02 )
was derived from standard formulas (15). Patients were
connected to the instrument through a mouthpiece that con-
tained a low resistance, nonrebreathing, three-way valve.
Calibration, using an analyzed mixture of approximately
4% carbon dioxide and 16% oxygen in nitrogen, was per-
formed before testing.
Blood oxygencontent. Retrograde femoral in and radial
artery catheterization was performed in six patients. A 7F
USCI catheter was introduced percutaneously through a 16
gauge Angiocath catheter and advanced 10 em distally into
the femoral vein, which contains, almost exclusively, blood
from the skeletal muscles (16,17). The radial artery was
cannulated with a smaller catheter (20 gauge Angiocath).
Blood samples were withdrawn from the femoral vein and
radial artery at rest, every I to 2 minutes during exercise
and at the time of exhaustion. Oxygen content was deter-
mined in duplicate using an oxygen analyzer (Lex-Os-Con-
TI, Lexington Instruments). Temperature and barometric
pressure corrections were made during each study. Cali-
bration of the oxygen analyzer was considered optimal if
three consecutive readings for dry air were within ± 0.1 / I00
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Figure l. Effects of long-term therapy with captopril on rest skel-
etal muscle blood flow and femoral arteriovenous oxygen differ-
ence.
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ml. Femoral arteriovenous oxygen difference wascalculated
as radial artery oxygen content minus femoral oxygen con-
tent.
Blood lactate determinations. Lactate measurements
were performed using a lactate analyzer (Roche Model 640).
Whole blood (10 nl) was hemolyzed immediately and di-
luted to a I :10concentration. Duplicate determinations were
performed. The lactate analyzer was calibrated with stan-
dardized 5 and 10 mmol lactate solutions before and during
sample determinations. Femoral vein lactate wasdetermined
at rest, every I to 2 minutes during exercise, at exhaustion
and I minute after cessation of exercise. The value reported
for peak exercise was the average of the determinations
made at exhaustion and I minute after the point of exhaus-
tion.
Statistical analysis. The results are expressed as mean
:±: SO, and were considered significant at p < 0.05 . Hemo-
dynamic anti metabolic changes were assessed using a two-
factor within-subject analysisof variance model during each
test. Patients were assessed at rest antiduring exercise before
anti after administration of captopril for a total of four ob-
servations. Hemodynamic and metabolic variables were
analyzed as a function of the effect of exercise, the inter-
vention (that is, repeat test or captopril) and the interaction
of the two factors. In the presence of interactions, F tests
for the single effects of the drug during exercise were per-
formed using orthogonal contrasts.
Results
Maximal VOz. Long-term therapy with captopril was
well tolerated in all eight patients. All felt subjectively im-
proved, except one whose symptoms remained unchanged.
Maximal V02 increased significantly from a control of 13.4
:±: 3.0 to 15.5 :±: 4.1 ml!kg per min (p < 0.(5) after an
average of Xweeks of therapy with captopril, However. the
increase in maximal V02 was less than I nil/kg per min in
four patients, while it averaged 3.7 ml!kg per min (range
2.7 to 4.9) in the remaining four patients.
Skeleta l muscle blood flow. At rest, this variable in-
creased significantly during long-term therapy with captopril
(from 1.5 :±: 0.6 to 2.6 :±: 1.0 mill 00 g per min, p < 0.05)
(Fig. I). Mean peak skeletal muscle blood flow attained
during exercise was not significantly increased (19.6 :±: 6.2
versus 27.6 :±: 14.3 mill00 g per min, p = NS). However,
in the four patients who experienced a significant increase
in maximal V02 , peak skeletal muscle blood flow increased
substantially from 19.6 to 34.5 mill 00 g per min. whereas
it was unchanged (19.7 versus Ig.2 ml!lOO g per min) in
the four patients who demonstrated only a minimal change
in maximal V02 . For the eight patients, the change in peak
skeletal muscle blood tlow attained during exercise corre-
lated closely with the change in maximal V02 (Fig. 2).
Femoral arteriovenous Oz difference and lactate. At
rest. femoral arteriovenous O~ difference decreased signif-
icantly (from 10.0 :±: 1.7 to 8.3 :±: 1.9 mill OO ml, p <
0.05) during long-term therapy with captopril, but was un-
Figure 2. Relation between changes in maximal oxygen uptake
and peak skeletal muscle blood flow during long-termtherapy with
captopril in eight patients with severe congestive heart failure .
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changed at peak exercise (12.6 ± 2.6 versus 12.6 ± 2.4
mlllOO ml). Femoral vein lactate determinations were ob-
tained in five patients. When compared with control values,
long-termtherapy with captopril did not significantlychange
femoral vein lactate at rest (II .7 ± 2.8 versus 10.7 ± 2.7
mg/IOO ml) or during exercise (57 ± 8 versus 69 ± 19
mg/IOO ml). However, in two patients who experienced a
significant increase in maximal V02 , femoral vein lactate
attained at peak exercise was substantially greater than con-
trol values (98.7 versus 65.4 and 70.0 versus 50.2 mgllOO
ml, respectively).
Submaximal exercise. The effects of chronic captopril
therapy on exercise capacity at submaximal and maximal
work loads were determined in one patient. Before admin-
istration of captopril, maximal work load was 75 W, which
could be sustained for only 4 minutes and led to a maximal
V02 of 20.0 ml/kg per min, skeletal muscle blood flow of
25.0 millOO g per min and femoral arteriovenous O2 dif-
ference of 15.2 mlllOO ml. Femoral vein lactate increased
during exercise and reached a maximum of 65.4 mgllOO
ml, After 8 weeks of therapy with captopril, the same work
load could be sustained for at least 10 minutes, at which
time the test was terminated electively by the investigators.
After 6 minutes of exercise, femoral vein lactate reached a
plateau of 46.0 mg/IOO m!. The maximal work load could
now be increased to 105 W, which then led to an increased
maximal V02 of 24.5 ml/kg per min, an increased peak
skeletal muscle blood flow of 54.5 mlllOO g per min and a
femoral arteriovenous O2 difference of 14.2 mlllOO m!. At
this increased work load, femoral vein lactate reached a
peak of 98.7 mg/IOO mi.
Discussion
The present study supports the view that during long-
term therapy with captopril in patients with severe conges-
tive heart failure, exercise performance, as measured by
maximal V02 , can be increased, but only in those patients
whose peak skeletal muscle blood flow is also increased.
Since the peak femoral arteriovenous O2 is unchanged, the
increase in maximal V02 is predicated by an increase in
skeletal muscle blood flow. Conversely, in those patients
whose peak skeletal muscle blood flow did not increase,
exercise performance was not improved. The close corre-
lation found between the change in peak skeletal muscle
blood flow and the change in maximal V02 demonstrates
the importance of skeletal muscle perfusion in determining
peak aerobic capacity, and is in agreement with the linear
relation between leg blood flowand V02 previously reported
(18-20) in normal subjects during bicycle exercise.
Short- versus long-term effects of captopril. The re-
sults of long-term therapy with captopril contrast with those
reported (5,6) with short-term administration, which fails
to improve skeletal muscle blood flow at rest and during
exercise despite an immediate enhancement of cardiac per-
formance. Such contrasting effects of short- and long-term
captopril therapy suggest that the effect of long-term therapy
with captopril on peak aerobic capacity probably is not
directly related to a reduction in angiotensin II plasma levels,
which is observed with short-term administration. A de-
crease in sympathetic nervous system activity mediated by
the decrease in angiotensin II also does not explain the
increase in peak aerobic capacity, because acute alpha-ad-
renergic blockade fails to improve maximal V02 (21,22).
Similarly, if changes in levels of kinins or prostaglandins
contributed directly to the peripheral vasodilatory response
to exercise, an increase in peak aerobic capacity would be
observed after short-term administration of captopri!.
A mechanism that could possibly explain the delayed
effect of captopril on peak skeletal muscle blood .flow is a
gradual improvement in sodium balance in patients with
severe congestive heart failure. Angiotensin-converting en-
zyme inhibition with captopril promotes renal excretion of
sodium through different pathways. It inhibits secretion of
aldosterone by the adrenal glands and augments renal blood
flow and glomerular filtration rate, thereby increasing the
delivery of sodium to distal sites in the renal tubule, where
loop diuretics act (23,24). Captopril also tends to reverse
toward normal the renal cortical microcirculatory abnor-
malities present in chronic heart failure (25). In addition,
proximal tubular reabsorption of sodium may be reduced
by decreased sympathetic tone mediated by captopril (26,27).
Whether or not captopril can promote sodium excretion by
increased synthesis of locally active natriuretic prostaglan-
dins on the kidney is still unclear (28-30). For all these
reasons, long-term therapy with captopril is likely to reduce
the elevated amount of total body sodium and, more spe-
cifically, the sodium content of the arteriolar wall, which
is an important determinant of vascular stiffness in patients
with heart failure (31-33). Inhibition of aldosterone by cap-
topril may also contribute to this effect. Thus, progressive
reduction in arteriolar wall sodium content should, in tum,
result in gradual improvement of the peripheral vasodilatory
response to exercise and, thereby, of peak aerobic capacity
(34). The improvement in exercise capacity noted within 2
weeks of diuretic drug therapy, which occurs despite a de-
crease in cardiac performance at rest, may be explained by
a similar mechanism (35).
Moreover, captopril could act directly on the ionic com-
position ofthe arteriolar wall in patients with severe chronic
heart failure. Experimentally, prolonged infusion of angi-
otensin II has been shown to increase intracellular sodium
permeability in the vascular smooth muscle (36). Con-
versely, long-term administration of captopril to sponta-
neously hypertensive rats has been found to reverse the
abnormal permeability of the vascular smooth muscle mem-
brane (37). Whether long-term therapy with captopril has a
direct action on the intracellular sodium content of the vas-
lACC Vol. 10. No.4
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cular smooth muscle in patients with chronic heart failure
is presently unknown.
Resting skeletal muscle blood flow. Although peak
skeletal muscle blood flow was significantly increased in
only four of the eight patients treated with captopril on a
long-term basis, skeletal muscle blood flow at rest increased
in all but one patient. Whether this increase at rest contrib-
uted to the subjective improvementreported by seven of the
eight patients is unclear at this time. Patients who do not
exercise at maximal intensity during their daily activities
could possibly benefit from an enhanced skeletal muscle
perfusion inducedby long-term therapy with captopril when
exercising at submaximal work loads. Alternatively. one
cannot rule out that a placebo effect may have occurred in
some patients. The discrepancy between subjective im-
provement and changes in maximal Y02 has also been ob-
served during double-blind therapeutic trials (38,39) and
points out thatmaximal skeletal muscle perfusion and. thereby.
peak aerobic capacity are insensitive indexes of efficacy
when assessing pharmacologic intervention in patients with
severe chronic heart failure.
References
I. Curtis C. Cohn IN. Vrobel T. Franciosa J. Role of the renin-angi-
otensin system in the systemic vasoconstriction of chronic congestive
heart failure. Circulation 1978:58:763-70.
2. Gavras H. Fawn DP. Berboken J. Brunner HR. Ryan TJ. Angiotensin
converting enzyme inhibition in patients with congestive heart failure.
Circulation 1979:58:770-6.
3. Davis R. Ribner H. Keung E. Sonnenblick E. LeJemtel T. Treatment
of chronic congestive heart failure with captopril. an oral inhibitor of
angiotensin converting enzyme. N Engl J Med 1979:301:117-21.
4. Kugler J. Maskin C. Frishman W. Sonnenblick EH. Le.lerntel TH.
Regional and systemic metabolic effects of angiotensin converting
enzyme inhibition during exercise in patients with severe heart failure.
Circulation 1982:66:1256-61 .
5. Wilson JR. Ferraro N. Effect of the renin-angiotensin system on limo
circulation and metabolics during exercise in patients with heart fail-
ure. J Am Coli Cardiol 1986:6:556-63.
6. Kramer BL. Massie BM. Topic N. Controlled trial of captopril in
chronic heart failure: a rest and exercise hemodynamic study. Cir-
culation 1983:67:807-16.
7. Captopril Multicenter Research Group. A placebo-controlted trial of
captopril in refractory chronic congestive heart failure. J Am Coli
Cardiol 19832:755-63.
8. Lassen N. Lindberg J. Minick O. Measurement of blood flow through
skeletal muscle by intramuscular injection of xenon I '.1 Lancet 1964:I:
686-9.
9. Tonnesen K. Blood flow through muscle during rhythmic contraction
measured by xenon':", Scand J Clin Lab Invest 1964:16:646-54.
10. Grimby G. Haggendal E. Saltin B. Local xenon!' clearance from the
quadriceps muscle during exercise in man. J Appl Physiol 1967:22:
305-10.
II. Clausen J. Lassen N. Muscle blood flow during exercise in normal
man studied by the xenon 11.1 clearance method. Cardiovasc Res 197J :5:
245-54.
12. Cerretelli P. Marconi C. Pendergast D. Meyer M. Heisler N. Piiper
J. Blood flow in exercising muscles by xenon clearance and by mi-
crosphere trapping. J Appl Physiol(Resp Environ Exer PhysioIl1984:56:
24-30.
13. Conn H. Equilibrium distribution of radioxenon in tissue: xenon-heme-
globin association curve. J Appl Physiol 1961:16:1065-70.
14. Davis L. Wexler L Rahinowitz A. et al. Data acquisition using a
scintillation detector interfaced to a personal microcomputer. J Nucl
Med 1985:26:85-7
15. Wilmore JH. Costill DL. Adequacy of the Holdane transformation in
the computation of exercise vo, in humans. J Appl Physiol 1973:35:
85-9.
16. Pernow H. Wahren J. Zelterquist S. Studies on the peripheral circu-
lation and metabolism in man. IV. Oxygen utilization and lactate
formation in the legs or healthy young men during strenuous exercise.
Acta Physiol Scand 1965:64:289-98.
17. Pernow B. Zelterquist S. A metabolic approach to the evaluation of
the nutritive blood flow. Scand J Clin Lab Invest 1967:99(suppl):90-4.
18. Jorfeldt L. Wahren J. Leg blood flow during exercise 111 man. Clin
Sci 1971:41:45'J-73.
19. Wahrcn J. Saltin B. Jorfeldt L. Pernow B. Influence of age on the
local circulatory adaptation to leg exercise. Scand J Clin Lab Invest
1984:33:79-86
20. Andersen P. Saltin B. Maximal perfusion of skeletal muscle in man.
J Physiol 1985:366:233-49
21. Remensnyder JP. Mitchell JH. Sarnoff SJ. Functional sympatholysis
during muscular activity. Circ Res 1962:II :370-80.
22. Kjellmer I. On the competition between metabolic' vasodilatation and
neurogenic vasoconstriction in skeletal muscle. Acta Physiol Scand
1965:6.1:450-9.
23. Dzau VJ. Colucci WS. Williams GH. Curfman G. Meggs L. Hollen-
berg NK. Sustained effectiveness of converting enzyme inhibition in
patients with severe congestive heart failure. N Engl J Med 1980:302:
137.\-9.
24. Packer M. Lee WHo Medina N. Yushak M. Influence of renal function
on the hemodynamic and clinical responses to long-term captopril
therapy in severe chronic heart failure. Ann Intern Med 1986:104:
147-54.
25. Ichikawa I. Pfeffer JM. Pfeffer MA. HostetterTM. Brenner 13M. Role
of angiotensin II in the altered renal function of congestive heart
failure. Circ Res 1984:55:669-75.
26. Slick Cit. Aguilera AJ. Zambriski EJ. Renal neuroadrencrgic trans-
mission. Am J Physiol IlJ75:229:60-5.
27. Mettuucr B. Rouleau JL. Bichet D. et al, Differential long-term in-
trarenal and neurohormonal effects of captopril and prazosin in patients
with chronic congestive heart failure: importance of initial plasma
renin activity. Circulation 1986:73:492-502.
28. Hollenberg NK. Renal response to angiotensin-converting enzyme
inhibition. Am J CanJiol 1982:49:1425-9.
29. Dzau V.I, Packer M, Lilly LS. Swartz SL. Hollenberg NK. Williams
GH. Prostaglandins in severe heart failure: relation to activation of
the renin-angiotensinsystem and hypernatremia. N Engl J Med 1984:310:
347-52.
30. Clive DM. StotT JS. Renal syndromes associated with nonsteroidal
ami-inflammatory drugs. N Engl J Med 1984:310:563-72
31. Zelis R. Dclca CS. Coleman HN, Mason or. Arterial sodium content
in experimental congestive heart failure. Circulation 1970:41:213-6.
32. Zelis R. Longhurst J. Capone RJ. Mason DT. A comparison of re-
gional blood flow and oxygen utilization during dynamic forearm
exercise in normal subjects and in patients with congestive heart fail-
ure. Circulation 197450: 1.17-43.
.13. Zelis R. Mason DT. Diminished forearm arteriolar dilator capacity
produced by mineralocorticoid-induced salt retention in man: impli-
cation concerning congestive heart failure and vascular stiffness. Cir-
culation 1970:41:5~9-96
34. Zelis R. Flaim SF. Liedtke J. Nellis SH. Cardiocirculatory dynamics
in the normal and failing heart. Annu Rev Physiol 1981:43:455-76.
850 MANCINI ET AL.
CAPTOPRIL AND SKELETAL MUSCLE BLOOD FLOW
35. Stampfer M, Epstein SE, Beiser GO, Braunwald E. Hemodynamic
effects of diuresis at rest and during intense upright exercise in patients
with impaired cardiac function. Circulation 1968;37:900-11.
36. Villamil MF, Nachev P, Kleeman CR. Effect of prolonged infusion
of angiotensin II on ionic composition of the arterial wall. Am I Physiol
1970;218:1281-6.
37. Ito K, Koike H, Mujamoto M, Ozaki H, Kishimoto T, Rakawa NU.
Long-term effects of captopril on cellular sodium content and me-
lACC Vol. 10, No.4
October 1987:845-50
chanical properties of aortic smooth muscle from spontaneously hy-
pertensive rats. I Pharmacol Exp Ther 1981;219:520-5.
38. Liang CS, Sherman LG, Doherty IU, Wellington K, Lee VW, Hood
WB. Sustained improvement of cardiac function in patients with
congestive heart failure after short-term infusion of dobutamine. Cir-
culation 1984;69: 113-9.
39. Braunwald E. Newer positive inotropic agents. Circulation 1986:73(suppl
111):237-9.
